T cell control of SARS-CoV-2: When, which, and where?

被引:6
|
作者
Diniz, Mariana O. [1 ]
Maini, Mala K. [1 ]
Swadling, Leo [1 ]
机构
[1] UCL, Inst Immun & Transplantat, Div Infect & Immun, Pears Bldg, London WC1E 6BT, England
基金
英国惠康基金;
关键词
SARS-CoV-2-specific T cells; Abortive infection; Tissue-resident; Mucosal vaccination; PROTECTION; VIRUS; INFLUENZA; RESPONSES; IMMUNITY; INFECTION; COVID-19; VACCINATION; ACTIVATION; CHALLENGE;
D O I
10.1016/j.smim.2023.101828
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Efficient immune protection against viruses such as SARS-CoV-2 requires the coordinated activity of innate immunity, B and T cells. Accumulating data point to a critical role for T cells not only in the clearance of established infection, but also for aborting viral replication independently of humoral immunity. Here we review the evidence supporting the contribution of antiviral T cells and consider which of their qualitative features favour efficient control of infection. We highlight how studies of SARS-CoV-2 and other coronaviridae in animals and humans have provided important lessons on the optimal timing (When), functionality and specificity (Which), and location (Where) of antiviral T cells. We discuss the clinical implications, particularly for the development of next-generation vaccines, and emphasise areas requiring further study.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2
    Henden, A.
    Lineburg, K.
    Le Texier, L.
    Raju, J.
    Crooks, P.
    Wright, E.
    Scott, A.
    Neller, M. A.
    Tey, S.
    Khanna, R.
    Smith, C.
    CYTOTHERAPY, 2023, 25 (06) : S252 - S252
  • [22] BCG and SARS-CoV-2 What Have We Learned?
    Kulesza, Jakub
    Kulesza, Ewelina
    Kozinski, Piotr
    Karpik, Wojciech
    Broncel, Marlena
    Fol, Marek
    VACCINES, 2022, 10 (10)
  • [23] Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion
    Eser, Tabea M.
    Baranov, Olga
    Huth, Manuel
    Ahmed, Mohammed I. M.
    Deak, Flora
    Held, Kathrin
    Lin, Luming
    Pekayvaz, Kami
    Leunig, Alexander
    Nicolai, Leo
    Pollakis, Georgios
    Buggert, Marcus
    Price, David A.
    Rubio-Acero, Raquel
    Reich, Jakob
    Falk, Philine
    Markgraf, Alissa
    Puchinger, Kerstin
    Castelletti, Noemi
    Olbrich, Laura
    Vanshylla, Kanika
    Klein, Florian
    Wieser, Andreas
    Hasenauer, Jan
    Kroidl, Inge
    Hoelscher, Michael
    Geldmacher, Christof
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [24] The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern
    Tennoe, Simen
    Gheorghe, Marius
    Stratford, Richard
    Clancy, Trevor
    VACCINES, 2022, 10 (07)
  • [25] Current understanding of T cell immunity against SARS-CoV-2
    Xiuyuan Lu
    Sho Yamasaki
    Inflammation and Regeneration, 42
  • [26] SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence
    La Sala, Lucia
    Gandini, Sara
    Bruno, Antonino
    Allevi, Raffaele
    Gallazzi, Matteo
    Senesi, Pamela
    Palano, Maria Teresa
    Meregalli, Paola
    Longhi, Ermanno
    Sommese, Carmen
    Luzi, Livio
    Trabucchi, Emilio
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] SARS-CoV-2 and Parkinson's Disease: A Review of Where We Are Now
    Boura, Iro
    Qamar, Mubasher A.
    Daddoveri, Francesco
    Leta, Valentina
    Poplawska-Domaszewicz, Karolina
    Falup-Pecurariu, Cristian
    Chaudhuri, K. Ray
    BIOMEDICINES, 2023, 11 (09)
  • [28] SARS-CoV-2 in humans
    Binder, Marco
    Wyler, Emanuel
    BERLINER UND MUNCHENER TIERARZTLICHE WOCHENSCHRIFT, 2021, 134
  • [29] SARS-CoV-2 vaccines, where do we stand?
    Fischer, Alain
    COMPTES RENDUS BIOLOGIES, 2021, 344 (01) : 43 - 55
  • [30] SARS-CoV-2 virus: Vaccines in development
    Huang, Qingrui
    Yan, Jinghua
    FUNDAMENTAL RESEARCH, 2021, 1 (02): : 131 - 138